Capecitabine and Docetaxel for Metastatic Oesophageal Cancer
Author Information
Author(s): Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F
Primary Institution: Technical University of Munich
Hypothesis
This trial assessed the efficacy, safety and feasibility of capecitabine in combination with docetaxel in patients with metastatic oesophageal cancer.
Conclusion
Capecitabine plus docetaxel has a manageable adverse event profile and promising activity in metastatic oesophageal cancer.
Supporting Evidence
- The overall response rate was 46%, with one complete and ten partial responses.
- The median time to progression was 6.1 months.
- The median survival time was 15.8 months.
- 42% of patients experienced grade 3/4 neutropenia.
Takeaway
Doctors tested a new medicine combination to help people with a tough kind of cancer, and it worked pretty well with not too many side effects.
Methodology
Patients received oral capecitabine and intravenous docetaxel every 3 weeks, and their responses were evaluated based on RECIST criteria.
Limitations
The small sample size limits definitive conclusions about the efficacy of this combination regimen.
Participant Demographics
Most patients were male (88%) with a median age of 61.5 years; 71% had squamous cell carcinoma.
Statistical Information
Confidence Interval
95% CI, 4.5–7.7 months for time to progression; 95% CI, 7.8–23.9 months for median survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website